Professor Nitzan Rosenfeld
Director, Barts Cancer Institute; Professor of Applied Cancer Research
The Rosenfeld group develops molecular diagnostic tools for cancer detection, characterisation and monitoring, to help make more informed treatment decisions. We focus on liquid biopsies, in which we analyse blood samples to detect and characterise cell-free circulating tumour DNA (ctDNA).
Professor Daniel M Berney
Honorary Professor of Genito-urinary Pathology; Consultant Pathologist
My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.
Professor Tatjana Crnogorac-Jurcevic
Professor of Molecular Pathology and Biomarkers
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
Professor Yong-Jie Lu
Professor of Molecular Oncology
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Dr Vivek Singh
Lecturer in Digital Pathology
Dr Jun Wang
Reader in Genomics and Data Science
I have broad research interests and experience in bioinformatics, cancer genomics and data analytics. These research areas mainly involve developing and applying bioinformatics and computational approaches to analyse large-scale cancer datasets to uncover novel diagnostic and prognostic biomarkers. I also lead the Cancer Research UK Barts Centre Bioinformatics Core Facility.
Dr Emma Bailey
I am providing bioinformatics support for several projects focusing on squamous cell carcinoma. This generally involves developing bioinformatics pipelines for large-scale cancer datasets and utilising computational approaches for analysis, with the overall aim being to uncover novel diagnostic and prognostic biomarkers.
Dr Oscar Maiques
Our research focuses on the principles of spatial biology, integrating digital pathology, multi-omic data, and various imaging modalities to explore tissue architecture and the tumour microenvironment.
Dr Megha Meena
We use novel mass cytometry technology following allogeneic haematopoietic stem-cell transplantation in patients, to define the global landscape of immune-cell populations preceding development of acute graft-versus-host disease (aGvHD) and to identify a dominant immunoregulatory role for subsets of CD56hi NK cells in limiting alloreative T-cell expansion and aGvHD.
Dr Max Palmer
My research focuses on implementing and developing novel radioisotopes for targeted alpha therapy and improving stability and pharmacokinetics of radiolabelled peptides.